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Abstract
Background The optimal strategy to prevent cytomegalo-
virus (CMV) disease after kidney transplantation continues to
be open to debate. The preemptive approach requires regular
determination of CMV viremia and prompt initiation of
therapy.
Methods We retrospectively compared the incidence of
CMV disease during two periods at our center: A first phase
(P1, n = 84 kidney recipients), during which time the inten-
sity of surveillance was determined by the responsible phy-
sician, was compared to a second phase (P2, n = 74), when a
stringent protocol of CMV surveillance was required for all
patients. The preemptive approach was applied for all CMV
risk groups; prophylaxis was optional in the case of treatment
for rejection or delayed graft function in the intermediate- and
high-risk group. Follow-up was truncated at 6 months after
transplant surgery. CMV syndrome was differentiated from
asymptomatic replication by the presence of at least one
systemic symptom, while diagnosis of CMV end-organ dis-
ease required histological confirmation.
Results Immunosuppression was similar in the two peri-
ods. CMV prophylaxis was used equally (26 %) in both
periods. The probability for asymptomatic viremia epi-
sodes was not different for patients in P1 and P2 regardless
of the prevention strategy. For patients following the pre-
emptive strategy, the probability for CMV disease was
increased during P1 (p = 0.016), despite fewer PCR assays
being performed in phase 2. Protocol violations were only
observed during P1.
Conclusions The probability of CMV disease episodes
(CMV syndrome and CMV end-organ disease) was sub-
stantially reduced using a very stringent protocol. This
study highlights the crucial importance of a stringent pro-
tocol with optimal adherence by all caregivers if the pre-
emptive strategy is to be successful.
Keywords Cytomegalovirus  CMV disease  Preemptive
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Introduction
Prevention of cytomegalovirus (CMV) disease after trans-
plantation remains a controversial and contentious issue. It has
recently been shown that high-risk (D?/R-) kidney allograft
recipients who receive prolonged prophylaxis for 6 months
have a lower rate of CMV disease, although late-onset CMV
disease still manifests in 16 % of the high-risk recipients [1].
In a similar study performed in high-risk kidney transplant
recipients in Europe, 37 % of the investigated patients
developed a CMV infection, and the majority were symp-
tomatic after 6 months of valganciclovir prophylaxis [2].
Despite the uncontested benefit of prophylaxis early after
transplantation, the problem of late-onset disease remains
unresolved. In contrast, the preemptive strategy, which
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requires a meticulous adherence to a regular surveillance
protocol and prompt initiation of therapy once an infection has
been detected, has been reliably associated with a low inci-
dence of late-onset CMV complications.
The aim of the study reported here was to assess the
effect of strict enforcement of a preemptive strategy on the
incidence of CMV disease by comparing two phases.
During the initial phase, a protocol was introduced into
daily outpatient care detailing the exact time-points of
CMV surveillance after transplantation and the thresholds
for the initiation of CMV preemptive therapy for recipients
at intermediate risk (recipient CMV-seropositive) and at
high risk (recipient CMV-seronegative, donor CMV sero-
positive). Implementation of the protocol was left to the
treating physician. In the second phase, adherence to the
protocol was actively supervised by a staff physician, who
had received additional instruction.
Subjects and methods
Patients
We retrospectively assessed the incidence of CMV infec-
tion and disease during the first 6 months after transplan-
tation in 158 consecutive kidney transplant recipients at our
institution between August 2007 and July 2009. During the
initial phase, a protocol was introduced into daily outpa-
tient care recommending time-points of CMV surveillance
and thresholds for the initiation of CMV preemptive ther-
apy for intermediate-risk [recipient CMV-seronpositive/
donor CMV-seronegative or -positive (R?/D±)] and high-
risk [recipient CMV-seronegative/donor CMV-seropositive
(R-/D?)] recipients. Between August 2007 and July 2008
(n = 84) the implementation of the surveillance protocol
was left to the discretion of the treating physician (P1). In
the second phase (P2), between August 2008 and July 2009
(n = 74), a similar, but more detailed preemptive protocol
was implemented, as described below, and used as an
official guideline; the implementation of this protocol was
actively supervised by a staff physician on each patient
visit.
Preemptive CMV protocol
The CMV status of the donor and recipient was evaluated
before transplantation. CMV monitoring was as follows:
for low-risk patients, CMV PCR and serology results were
required at months 3 and 6, or upon clinical suspicion for
CMV infection; for intermediate-risk and high-risk
patients, CMV PCR results were required on a weekly
basis during month 1, then every other week for the next
2 months, and thereafter once a month until month 6.
For high-risk patients, serology testing was scheduled at
months 3 and 6. CMV therapy was indicated whenever
CMV DNA was detectable (high-risk patients) or crossed a
threshold of [2,000 copies/ml (intermediate-risk patients).
At our center, we use an in-house plasma-based CMV real-
time PCR assay.
The protocol allowed primary prophylaxis for the fol-
lowing conditions: (1) treatment with antithymocyte glob-
ulin (ATG) for induction; (2) delayed graft function; (3)
rejection treatment of any kind. The duration of prophy-
laxis ranged from 1 to 3 months. Both the use of val-
ganciclovir and valaciclovir (two patients) was counted as
prophylaxis. The dosage used was according to the rec-
ommendation of the manufacturer, including adjustment
for renal insufficiency. Of note, no breakthrough CMV
disease was recorded while the patients received prophy-
laxis. CMV disease was defined in accordance to published
definitions [3]. Cases with CMV viremia without clinical
symptoms were documented as asymptomatic viremia.
Viral syndrome was defined as CMV PCR positivity in the
blood and one of the following symptoms with no other
explanation: fever, leukopenia, elevated transaminases, or
unspecified malaise. End-organ disease was defined as the
detection of CMV in the biopsy by immunohistochemistry.
CMV PCR positivity in the blood, typical symptoms of
end-organ disease (colitis), and no other diagnosis were
considered to be signs of viral syndrome. Valganciclovir
was the treatment of choice for asymptomatic CMV vire-
mia, while intravenous ganciclovir was used for CMV
disease if patients required hospitalization.
The real-time PCR assay for CMV is based on the
protocol of Yun et al. [4] The target sequence is the viral
glycoprotein B. The linear range of the assay extends from
8 9 10E2 to 8 9 10E7 IU/ml, and the 95 % confidence
interval of the precision within this range is 3/4 0.5 log10.
The lower limit of detection is \8 9 10E1 IU/ml. Cali-
bration against the World Health Organization (WHO)
standard resulted in a value of 0.4 IU/genome copy.
Intervention
To improve adherence to the protocol, an official written
guideline was distributed to all physicians in the nephrol-
ogy outpatient clinic and regular teaching sessions were
held to emphasize the importance of a strict follow-up. The
supervising physician reviewed each visit. Each positive
CMV PCR result was assessed not only by the treating
physician but also discussed with the supervisor.
Rejection
The definition of rejection was based on typical histopa-
thological findings on a kidney biopsy using the Banff
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classification, or in few cases in a raising serum creatinine
without any other explanation [5]. Rejection treatment
consisted of pulses of methylprednisolone, ATG antibody
or, rarely, immunoadsorption if patients were not
responding.
Statistical analysis
Follow-up was truncated at 6 months for all patients.
Fisher’s exact, chi-square, and Wilcoxon rank-sum tests
were used as appropriate. For the time to event analysis,
Kaplan–Meier curves with the log rank-test were used to
compare episodes. Analysis was performed separately for
patients receiving prophylaxis and patients with a pre-
emptive strategy.
Results
Patient characteristics
Age, gender, cause of end stage kidney failure, gender, and
source of organ were comparable between the two phases
(Table 1). Percentage of CMV high-risk recipients was
higher in phase 1 (24 vs. 12 %), while intermediate-risk
recipients accounted for more patients during phase 2 (66
vs. 57 %). The overall percentage of recipients with CMV
prophylaxis was 26 % in both phase 1 and in phase 2
(Table 2a).
In total, 46 (55 %) of patients in phase 1 and 45 (61 %)
of patients in phase 2 never used any CMV-active drug
during the entire follow-up observation.
Asymptomatic viremia
In total, 39 episodes of asymptomatic viremia were
detected during phase 1, 31 in recipients without pro-
phylaxis, and eight in patients after stopping prophylaxis.
The corresponding numbers were 35 episodes during
phase 2, with 30 episodes in patients with a preemptive
strategy and five in recipients after completion of pro-
phylaxis (Fig. 1). As expected, the probability of
asymptomatic viremia was higher in the population
without prophylaxis than in the patients receiving pro-
phylaxis. There was no statistical difference when the
probability of asymptomatic viremia was analyzed
between phase 1 and 2 in both the preemptive group and
the prophylaxis group.
CMV disease: viral syndrome and end-organ disease
A total of 14 patients developed a viral syndrome attrib-
utable to CMV: 12 (14 %) in phase 1 and two (2.7 %) in
phase 2. Four patients were diagnosed with end-organ
disease, two (2.4 %) in phase 1 and two (2.7 %) in phase
2. Excluding the patients who received prophylaxis, nine
CMV disease episodes were recorded during phase 1 and
one during phase 2 (p = 0.016), when the two clinically
relevant endpoints, i.e., viral syndrome and end-organ
disease, were combined (Fig. 2). Importantly, using the
combined endpoint viral syndrome and end-organ disease,
in the high-risk group, three of 11 patients in phase 1 and
neither of the two patients in phase two had clinical dis-
ease. In the intermediate-risk group, six of 35 patients
during phase 1 and one of 38 patients had clinical
diseases.
Table 1 Characteristics of
patient population
IQR Interquartile range
Characteristics of patient population Phase 1 (n = 84 patients) Phase 2 (n = 74 patients)
n 84 74
Age, median (IQR) 51.6 (43.6–60.3) 50.2 (43.5–57.1)
Gender, male (%) 60 (71) 47 (63)
Living donor (%) 28 (33) 22 (30)
AB0 mismatch in living donor (%) 2 (2) 7 (9)
Deceased donor (%) 56 (67) 52 (70)
Causes of terminal kidney failure
Glomerulonephritis (%) 26 (31) 21 (28)
Diabetic nephropathy (%) 15 (18) 19 (26)
Polycystic kidney disease (%) 13 (15) 8 (11)
Hypertensive nephropathy (%) 4 (5) 4 (5)
Chronic pyelonephritis (%) 3 (4) 2 (3)
Hemolytic uremic syndrome (%) 2 (2) 1 (1)
Other (%) 10 (12) 7 (9)
Unknown etiology (%) 11 (13) 12 (16)
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Median CMV PCR load was 8,900 copies/ml (range
1,970–85,000 copies/ml) at the time of start of therapy
(phase 1, only preemptive patients); in phase 2, the only
patient with a CMV episode presented with low viremia
but clinical symptoms of colitis. During phase 1, therapy
was started according to the guidelines in five of the nine
CMV patients, while there was a delay of 9.5 days (range
3–16 days) in the four remaining patients. In phase 2, the
Table 2 Cytomegalovirus risk groups and prevention strategies
a Prevention strategies Phase 1a (n = 84
patients)
Phase 2a (n = 74
patients)
p value
CMV risk, n (% of all patients, n = 158) 0.17b
Low 16 (19) 16 (22)
Intermediate 48 (57) 49 (66)
High 20 (24) 9 (12)
Preemptive strategy, n (% of patients receiving preemptive therapy, n = 117) 0.047c
Low 16 (26) 15 (27)
Intermediate 35 (56) 38 (70)
High 11 (18) 2 (4)
Prophylaxis, n (%, patients under prophylaxis, n = 41) 0.74c
Low 0 (0) 1 (6)
Intermediate 13 (59) 11 (58)
High 9 (41) 7 (37)
Number of patients who did not receive drugs for CMV throughout study,
n (%)
46 (55) 45 (61) 0.59b
b CMV diseases patients receiving preemptive strategy (total patients in the respective risk group)
Low 0 (16) 0 (15)
Intermediate 6 (35) 1 (38)
High 3 (11) 0 (2)
CMV Cytomegalovirus
a Phase 1 (P1), treatment phase during which time the intensity of surveillance was determined by the responsible physician; Phase 2 (P2), when
a stringent protocol of CMV surveillance was required for all patients (preemptive protocol)
b Chi-square test
c Fisher’s exact test
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Fig. 1 Probability of asymptomatic cytomegalovirus (CMV) viremia
after transplantation in patients followed by the preemptive strategy.
During the study, 31/62 patients (phase 1) and 30/55 patients (phase
2) experienced asymptomatic CMV viremia (p = 0.71)
0.00
0.25
0.50
0.75
1.00
Pr
ob
ab
ilit
y 
of
 s
ym
pt
om
at
ic 
vir
em
ia
0 2 4 6
Time (months)
Phase 1 Phase 2
logrank-test p=0.016Patients under preemptive strategy, n=117
Fig. 2 Probability of CMV disease (viral syndrome and CMV end-
organ disease) in patients receiving the preemptive strategy. In total,
nine of 62 patients (phase 1) and one of 55 patients (phase 2)
experienced a CMV disease episode (p = 0.016)
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one patient was treated according to protocol. Among the
high-risk patients, seroconversion was seen in three
patients (15 %; phase 1) and one patient (8 %, phase 2).
CMV surveillance
The mean number of CMV PCR determinations per patient
was assessed in the preemptive group and compared to the
number required by the surveillance protocol. Surprisingly,
only 91 (intermediate-risk recipients) and 59 % (high-risk
recipients) of the required CMV PCR determinations were
performed during phase 2, a lower proportion than in phase
1 (131 and 99 %, respectively) (Fig. 3a, b). Only regular
CMV PCR determinations obtained before any type of
event (asymptomatic viremia or CMV disease) and cor-
rected for missing time were included in the analysis.
Immunosuppressive treatment
Immunosuppresive treatment was analyzed during the first
week after transplantation and at 4 weeks after transplan-
tation (Table 3).
In phase 1, 13 (15 %) patients received an induction
treatment [5 with ATG, 6 with basiliximab, and 2 with
rituximab (ABO-incompatible kidneys)]; in phase 2, 18
(24 %) patients had an induction therapy (7 with ATG, 4
with basiliximab, and 7 with rituximab). The initial drug
therapy for phase 1 patients was cyclosporine (47 patients,
56 %), tacrolimus (21, 25 %), and a non-calcineurin
inhibitor (CNI)-based treatment (13, 15 %). In phase 2,
fewer patients were initially treated with cyclosporine (22,
30 %) as their first CNI, while 45 (61 %) patients were
initially started on tacrolimus and six (8 %) patients with
other drugs.
Regular triple immunosuppressive maintenance was
used in which an antimetabolite, CNI, and steroid drugs
were combined. Four weeks after transplantation, in phase
1, 44 (52 %) patients were receiving cyclosporine, 39
(46 %) patients had tacrolimus, and one (1 %) patient
received neither. In phase 2, 22 (30 %) patients were
receiving cyclosporine, 49 (66 %) patients had tacrolimus,
and three (4 %) patients had another non-CNI-based
regimen.
Rejections, transplant failure, reduced graft function,
and death
No difference was observed between phases in terms of
rejections [45 (phase 1) vs. 42 % (phase 2); p = 0.67].
Fourteen patients (17 %) in phase 1 and 12 patients (16 %)
in phase 2 had a calculated glomerular filtration rate (GFR)
of \30 ml/min at the end of the 6-month observation
period (p = 0.94). The number of transplant failures was
slightly lower in phase 2 [8 (phase 1) vs. 4 % (phase 2);
p = 0.34). No CMV-related deaths were observed
(Table 4).
Discussion
The prevention of CMV disease after solid organ trans-
plantation has considerably reduced morbidity and mor-
tality and is a cornerstone of every transplant program
regardless of the organ transplanted. The availability of
efficient drugs against CMV has led to different prevention
strategies. Prophylaxis is given to all patients at risk, usu-
ally for a defined period. Preemptive therapy uses a marker,
such as CMV PCR or pp65 assay results, to detect repli-
cation before the onset of disease. Therapy is initiated in
order to prevent clinical disease. Both strategies have their
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Fig. 3 a Mean number of CMV PCR determinations performed
during phase 1 and phase 2, respectively. Only determinations in
patients followed by the preemptive strategy and before the occur-
rence of a CMV event are analyzed and corrected for missing time.
b Percentage of CMV PCR determinations according to CMV risk
stratification and phase
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clear benefits and dangers. The current guidelines prefer
prophylaxis, at least for the high-risk constellation of a
CMV-seronegative recipient of an organ from a CMV-
seropositive donor [6]. The ease of prophylaxis treatment
and the documented benefits in term of mortality is coun-
terbalanced by the potential side effects, such as cytopenia
and the occurrence of late-onset CMV disease. A longer
period of prophylaxis (6 months) has been shown to further
reduce late-onset CMV disease [1], but increased costs are
an issue. Important considerations are the indirect effects of
CMV on transplant-related endpoints, such as rejection and
long-term graft function, which are linked to CMV by
circumstantial evidence. Some studies show an advantage
of prophylaxis over preemption for these indirect effects
[7], while others do not [8, 9]. The major hurdles for the
preemptive strategy are the logistics necessary not only to
ensure timely assessment of biomarkers, but also to take
appropriate and prompt action upon receipt of the result. At
our center, we became aware that while CMV PCR
determinations were performed regularly, taking action
upon learning of a positive result was often delayed. For
the two periods studied, CMV PCR results were automat-
ically transmitted to the electronic patient file, where they
had to be looked up actively, as compared to the time
before, where they were communicated by telephone and
were therefore less likely to be missed. After adopting a
stringent control mechanism, we analyzed the incidence of
CMV events before and after implementation and found a
significant decrease of CMV disease events even though
CMV viremia was assessed less often. The overall inci-
dence of CMV disease was significantly reduced from 14
cases (17 %) in phase 1 to four cases (5 %) in phase 2.
Importantly, this reduction held true even when only the
patients without prophylaxis were analyzed separately [9
(11 %) in phase 1 vs. 1 (1 %) in phase 2], demonstrating a
strong impact of strict adherence to the protocol.
Retrospective analyses are always prone to systematic
biases. However, no new immunosuppressive strategy was
introduced during the observation period, and the charac-
teristics of the patient population were comparable between
phase 1 and 2. There was an imbalance of more patients
receiving an ABO-incompatible living donor kidney
transplant in phase 2, but the small number precluded any
statistical analysis. Importantly, the imbalance in the per-
centage of high-risk patients between phase 1 and 2 in the
group followed preemptively did not account for the dif-
ferences seen in CMV diseases. Of the two patients at risk
in phase 2, none had a CMV disease episode, while three of
11 patients had a disease episode, which was fewer than
expected. However, while only one of 38 patients at
intermediate risk showed a clinical episode of CMV dis-
ease in phase 2 compared to six of 35 patients during phase
1. Taken together, we believe that it is very unlikely that
other systemic factors were responsible for the difference
seen in CMV disease endpoints between the two phases.
Prophylaxis was given to 26 % of the patients in both
groups. The duration of the treatment varied from 1 to
3 months, which explains why asymptomatic viremia was
detected before month 3 in some patients. No CMV viremia or
CMV disease occurred in patients receiving prophylaxis.
The observation period was too short and the numbers to
small to make a statement on common endpoints, such as
graft rejection, GFR, graft failure, or death.
Table 3 Induction and
maintenance
immunosuppressive treatment at
weeks 0 and 4
a Chi-square test
b Fisher’s exact test
Immunosuppressive treatment Phase 1
(n = 84 patients)
Phase 2
(n = 74 patients)
p value
Induction treatment, n (%)
Antithymocyte globulin 5 (6) 7 (9) 0.55a
Basiliximab (%) 6 (7) 4 (5) 0.75a
Rituximab 2 (2) 7 (9) 0.084a
Maintenance treatment at 0 and 4 weeks after transplant (0/4), n (%)
Cyclosporine 47 (56)/44 (52) 22 (30)/22 (30) 0.001/0.004b
Tacrolimus 21 (25)/39 (46) 45 (61)/49 (66) \0.001/0.012b
Other immunosuppressive drug 13 (15)/1 (1) 6 (8)/3 (4) 0.22/0.051a
Table 4 Rejection, graft function, and death
Phase 1
(n = 84
patients)
Phase 2
(n = 74
patients)
p value
One or more graft
rejection, n (%)
38 (45) 31 (42) 0.67b
GFRa \30 ml/min at
month six, n (%)
14 (17) 12 (16) 0.94b
Graft failure, n (%) 7 (8) 3 (4) 0.34c
Deaths, n (%) (none
was CMV-related)
1 (1) 4 (5) 0.19c
a Glomerular filtration rate; calculated according to the (Modification
of Diet in Renal Disease (MDRD) formula
b Fisher’s exact test
c Chi-square test
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The overall rate of patients with end-organ disease was
low [2 (2 %) in phase 1 vs. 2 (3 %) in phase 2]. A number
of studies have shown that prophylaxis is cost-effective;
however, the rate of asymptomatic viremia and CMV
disease was higher in those studies than in our study [10].
We are currently performing a cost analysis to determine
the impact of our low incidence of CMV disease on overall
costs. Notably, over 55 % of all patients never were treated
with any kind of drug directed against CMV.
A surprising finding is that despite the better outcome
during phase 2, fewer CMV PCR determinations were
performed in phase 2 than in phase 1. The difference is
small when the absolute number of PCR determinations
performed is compared (7 vs. 5). Only viremia assessed
prior to any detection of CMV was counted as a PCR
determination, as the frequency of assessments was altered
by the detection of CMV. The mean number of CMV PCR
determinations performed before the occurrence of a
clinical endpoint (viral syndrome or end-organ disease)
was lower in phase 1 (6 determinations) than in phase 2
(8 determinations). Due to the low number of events, no
statistical significance was reached. However, this obser-
vation is contrary to the mean number of PCR determina-
tions performed overall. The same is true when the days
between the last positive CMV PCR and any clinical
endpoint were calculated. Of all patients who should have
started therapy according to the guidelines, none were
missed during phase 2, while four patients during phase 1
(preemptive group) did not receive the appropriate treat-
ment, with a median delay of start of therapy of 9.5 days.
This delay may explain in part the difference in outcome
observed. Our patients all live close to the transplant cen-
ter, and the follow-up is performed at the transplant center
within the first year. These circumstances certainly facili-
tate a uniform approach and a meticulous adherence to the
preemptive protocol.
At our center, preemptive therapy is a safe option, but
requires a close adherence to the protocol. A constant
investment in teaching and surveillance is necessary to
maintain a high compliance with the preemptive protocol.
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